Mia's Feed
Medical News & Research

NIH Sets Limit on Publishing Fees for Publicly Funded Research by 2026

NIH Sets Limit on Publishing Fees for Publicly Funded Research by 2026

Share this article

NIH to implement a cap on publishing fees for research funded by the government starting in 2026, aiming to reduce costs and improve access to scientific findings.

1 min read

The National Institutes of Health (NIH) has announced a new policy to limit publisher fees for research funded by the government, effective by the start of Fiscal Year 2026. This initiative aims to make publishing more affordable and accessible, addressing concerns over the high costs associated with open access publishing. Currently, some top medical journals charge as much as $13,000 per article for immediate open access, and these publishers also impose substantial subscription fees on government agencies. The NIH argues that such costs lead to an unnecessary financial burden on taxpayers, as their taxes have already supported the underlying research. While the specific cap on publishing fees has yet to be disclosed, the NIH's goal is to ensure that publication costs remain reasonable across the board. This move is part of a broader effort to promote the dissemination of research findings without imposing extra financial barriers. NIH Director Jay Bhattacharya stated that this policy is a critical step in safeguarding the integrity of scientific publishing and maximizing the public benefit from federally funded research.

Stay Updated with Mia's Feed

Get the latest health & wellness insights delivered straight to your inbox.

How often would you like updates?

We respect your privacy. Unsubscribe at any time.

Related Articles

Global Study Reveals Widening Scale of Infant Malnutrition, Urging Immediate Action

A new global study uncovers the widespread and alarming extent of malnutrition among infants under six months, calling for immediate health interventions to save millions of vulnerable lives.

Reevaluation of Adolescent Depression Medication Trial Highlights Potential Risks of SSRIs

A new reanalysis of a pivotal adolescent depression trial reveals that fluoxetine may pose significant safety risks, questioning its widespread use. Learn more about the findings and implications for mental health treatment in teenagers.